Acute leukemia in adults

Current Opinion in Hematology

Volumn 3, Issue 4, 1996, Pages 259-265

  Minden, Mark ^a   Imrie, Kevin ^a   Keating, Armand ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CYTOGENETICS; DOSE CALCULATION; HUMAN; LEUKEMIA CELL; ONCOGENE; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; TUMOR SUPPRESSOR GENE;

EID: 0030035784     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199603040-00003     Document Type: Review

References (39)

1. Berman E: Chemotherapy in acute myelogenous leukemia: high dose, higher expectations? J Clin Oncol 1995, 13:1-4. A brief critical assessment of increasing treatment dose intensity for patients with AML.
2. Mayer RJ, Davis RB, Schiffer CA, et al.: Intensive postremission chemotherapy in adults with acute myelold leukemia. N Engl J Med 1994, 331:896-903.
3. Imrie K, Dicke KA, Keating A: Autologous bone marrow transplantation • for acute myeloid leukemia. Stem Cells 1996, 14:69-78. A review of trials comparing chemotherapy, autotransplants and allotransplants for acute myeloid leukemia.
4. Mitus JM, Miller KB, Schenkein DP, et al.: Improved survival for patients • with acute myelogenous leukemia. J Clin Oncol 1995, 13:560-569. An entire cohort is followed from diagnosis of AML.
5. Kanamaru A, Takemoto Y, Tanimoto M, et al.: All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 1995, 85:1202-1206.
6. Licht JD, Chomienne C, Goy A, et al.: Clinical and molecular characteri•• zation of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 1985, 85:1083-1094. This paper describes a group of patients with a variant form of APL. The striking feature is the lack of response to all-trans retinoic acid.
7. Rogaia D, Gngnani F, Nicoletti I, et al.: The acute promyelocytic •• leukemia specific PML/RAR alpha fusion protein reduces the frequency of commitment to apoptosis upon growth factor deprivation of GM-CSF dependent myeloid cells. Leukemia 1995, 9:1467-1472. PML/RAR acts to reduce apoptosis in the absence of growth factor.
8. Dyck JA, Warrell RP, Evans RM, et al.: Rapid diagnosis of acute promyelocytic leukemia by immunohistochemical localization of PML/RAR-alpha protein. Blood 1995, 85:862-867. This paper describes the use of antibodies against PML to make the diagnosis of APL and to monitor response to therapy. This is likely to be of value in routine management of patients and offers the most rapid method to date to make a firm diagnosis of APL.
9. Fukutani H, Naoe T, Ohno R, et al.: Prognostic significance of the RT-•• PCR assay of PML-RARA transcripts in acute promyelocytic leukemia. The Leukemia Study Group of the Ministry of Health and Welfare (Kouseisho). Leukemia 1995, 9:588-593. This study confirms previous work suggesting that patients who test negative for PML-RAR following therapy have a high probability of long-term remission and need not be considered for an early bone marrow transplant.
10. Tobal K, Saunders MJ, Grey MR, et al.: Persistence of RAR alpha-PML •• fusion mRNA detected by reverse transcriptase polymerase chain reaction in patients in long term remission of acute promyelocytic leukemia. Br J Haematol 1995, 90:615-618. This study suggests that, as in the case of t(8;21), even in long-term remissions there is persistence of the leukemic clone. This has important implications in our understanding of remission and the regulation of leukemic cell growth.
11. Fukutani H, Naoe T, Ohno R, et al.: Isofoms of PML-retinoic acid recep•• tor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all trans retinoic acid. The Leukemia Study Group of the Ministry of Health (Kohseisho). Leukemia 1995, 9:1478-1482. This study calls into question previous work that places prognostic significance on the location of the breakpoint in t(15;17).
12. Gallagher RE, Li YP, Rao S, et al.: Characterization of acute promyelocytic leukemia cases with PML-RAR alpha break/fusion sites in PML exon 6: identification of a subgroup with decreased in vitro responsiveness to all trans retinoic acid. Blood 1995, 86:1540-1547.
13. Harousseau JL, Wu D: The use of GM-CSF and G-CSF in the treatment • of acute leukemias. Leuk Lymphoma 1995, 18:405-412. A review of colony-stimulating factors in the treatment of acute leukemia.
14. Rowe JM, Anderson JW, Mazza JJ, et al.: A randomized placebo-• controlled phase III study of granulocyte-macrophage colony stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the eastern cooperative oncology group (E1490). Blood 1995, 86:457-462. A randomized, double-blind, placebo-controlled trial of GM-CSF compared with placebo in addition to conventional induction and consolidation. This trial demonstrated that the addition of GM-CSF decreased toxicity and improved survival.
15. Stone RM, Berg DT, George SL, et al. for the Cancer and Leukemia • Group B: Granulocyte-macrophage colony stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 1995, 332:1671-1677. This randomized, double-blind placebo-controlled trial of GM-CSF compared with placebo after induction chemotherapy failed to show any benefit for GM-CSF although it confirmed that GM-CSF did not stimulate regrowth of leukemia.
16. Dombret H, Chastang C, Fenaux P, et al.: A controlled study of recombi• nant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 1995, 332:1678-1683.
17. Cahn JY, Labopin M, Mandelli F, et al.: Autologous bone marrow transplantation for first remission acute myeloblastic leukemia in patients older than 50 years: a retrospective analysis of the European Bone Marrow Transplant Group. Blood 1995, 85:575-579.
18. Horowitz MM, Messerer D, Hoelzer D, et al.: Chemotherapy compared with acute lymphoblastic leukemia in first remission. Ann Intern Med 1991, 115:13-18.
19. Zhang MJ, Hoeizer D, Horowitz MM, et al.: Long-term follow-up of adults • with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. Ann Intern Med 1995, 123:428-431. Long-term follow-up of the 1991 study by Horowitz et al. (Ann Intern Med 1991, 115:13-18) validating the earlier work.
20. Attal M, Blaise D, Marit G, et al.: Consolidation treatment of adult acute • lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1995, 86:1619-1628. Allotransplants are associated with improved disease-free survival but interleukin-2 after autotransplantation did not change outcome.
21. Copelan EA, McGuire EA: The biology and treatment of acute lymphoblastic leukemia in adults. Blood 1995, 85:1151-1168. A comprehensive review of ALL.
22. Barrett AJ, Horowitz MM, Ash RC, et al.: Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1992, 70:3067.
23. Stockschlader M, Hegewisch-Becker S, Kruger W, et al.: Bone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 1995, 16:663-667.
24. Ottmann OG, Hoeizer D, Gracien E, et al.: Concomitant granulocyte colony-stimulating factor and induction chemotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. Blood 1995, 85:444-450.
25. Xie XY, Robb D, Chow S, et al.: Discordant P-glycoproteln antigen •• expression and transport function in acute myeloid leukemia. Leukemia 1995, 9:1882-1887. Some patients have high levels of P-glycoprotein and low efflux and others have low levels of P-glycoprotein with high efflux. This indicates that P-glycoprotein assays are inadequate as a means of assessing drug resistance and suggests other proteins are involved in mediating drug efflux.
26. Zhou DC, Zittoun R, Marie JP: Expression of multidrug resistance associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia 1995, 9:1661-1666. Demonstrates the expression of a second protein on the surface of leukemic cells involved in multidrug resistance.
27. Keith FJ, Bradbury DA, Zhu M, et al.: Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to ara-c. Leukemia 1995, 9:131-138.
28. Hu Z, Minden MD, McCulloch EA: Direct evidence for the participation • of bcl-2 in the regulation of retinoic acid of the ara-c sensitivity of leukemic cells. Leukemia 1995, 9:1667-1673. Demonstrates the potential importance of Kit expression by AML cells in vivo in supporting the growth of factor dependent cells.
29. Hu Z, Ynag GS, Li M, et al.: Mechanism of cytosine arabinoside toxicity •• to the blast cells of acute myeloblastic leukemia. Leukemia 1995, 9:789-798. Suggests that in addition to acting as a chain terminator, an important aspect of cytosine arabinoside-induced cytotoxicity is the generation of reactive oxygen intermediates.
30. Cuneo A, Ferrant A, Michaz JL, et al.: Cytogenetic profile of minimally differentiated (FAB MO) acute myeloid leukemia: correlation with clinicobiologic findings. Blood 1995, 85:3680-3694. Cytogenetic abnormalities associated with AML-MO are described.
31. Dastugue N, Payen C, Lafage-Pochitaloff M, et al.: Prognostic signifi•• cance of karyotype in de novo adult acute myeloid leukemia: the BGMT group. Leukemia 1995, 9:1491-1498. Describes the prognostic significance of different cytogenetic abnormalities in a large group of patients.
32. Domer PH, Head DR, Renganathan N, et al.: Molecular analysis of 13 • cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4;11). Leukemia 1995, 9:1305-1312. In this paper the authors provide a mechanism by which topoisomerase II inhibitors play a role in translocations of MLL at 11q23.
33. Nakamaki T, Kawamata N, Schwaller J, et al.: Structural integrity of the cyclin dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukemias. Br J Haematol 1995, 91:139-149. One of a series of papers demonstrating that abnormalities of p15 and p16 are rare in AML but quite common in ALL.
34. Menssen HD, Renkl HJ, Rodeck U, et al.: Presence of Wilms' tumor •• gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1985, 9:1060-1067. Confirms previous studies of WT1 expression in AML and shows by immunostaining the localization of the protein in the nuclei of almost all of the leukemic cells.
35. Maheswaran S, Englert C, Bennett P, et al.: The WT1 gene product stabilizes p53 and inhibits p53 mediated apoptosis. Genes Dev 1995, 9:2143-2156. Provides a possible role of WT1 in malignant transformation by suppressing the effect of wild-type p53.
36. Matsumara I, Kanakura Y, Kato T, et al.: Growth response of acute • myeloblastic leukemia cells to recombinant human thrombopoietin. Blood 1995, 86:703-709. Shows that a large fraction of AML cells can respond to thrombopoietin in culture.
37. Piacibello W, Fubini L, Sanavio F, et al.: Effects of human FLT3 ligand on • myeloid leukemia cell growth: heterogeneity in response and synergy with other hematopoietic growth factors. Blood 1995, 86:4105-4114. This paper shows that a large fraction of AML cells can respond to Flt3 ligand either alone or in combination with other growth factors.
38. Hu Q, Trevisan M, Xu Y, et al.: c-Kit expression enhances the leukemogenic potential of 32D cells. J Clin Invest 1995, 95:2530-2538. This paper demonstrates that the constitutive expression of kit by factor-dependent cells allows the cells to survive and proliferate in vivo, presumably by interacting with endogenously expressed kit ligand. This is of importance in trying to understand which of the factors that leukemic cells respond to in culture are important for in vivo growth.
39. Rogers SY, Bradbury D, Kozolowski R, et al.: Evidence for internal • autocrine regulation of growth in acute myeloblastic leukemia cells. Exp Hematol 1995, 22:593-598. This paper is a continuation of work demonstrating the importance of GM-CSF production by AML cells in regulating their growth.